Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

Also called NCT05419115

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05419115
Other papers using this trial's data
  • Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure Journal of the American College of Cardiology, 2026-10-13 DOI, PubMed 42872757

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05419115. Randomized; no masking; primary purpose treatment. Start 2022-11-17 (actual); primary completion 2026-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure
Acronym
SUBCUT-HF II
Condition
Heart Failure
Intervention (Drug)
SQIN-Furosemide
Intervention (Device)
SQIN-Infusor
Lead sponsor
NHS Greater Glasgow and Clyde (class: other)
Collaborator
University of Glasgow (class: other)

Record details

Record id
cardio:ct-nct05419115
Content hash
9f350a834fdd5aff405d164070cd7740b3d3759149a006e310235b033781e3d6